Skip to main content
Clinical Trials/JPRN-jRCT1090220212
JPRN-jRCT1090220212
Completed
未知

Prospective observational study of SGLT2 inhibitor, tofogliflozin in patients with type 2 diabetes - Prospective observational study of tofogliflozin in patients with type 2 diabetes

agoya Medical Association0 sites600 target enrollmentApril 8, 2015
ConditionsType 2 Diabetes

Overview

Phase
未知
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
agoya Medical Association
Enrollment
600
Status
Completed
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
April 8, 2015
End Date
January 26, 2019
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
agoya Medical Association

Eligibility Criteria

Inclusion Criteria

  • \*Patients with type 2 diabetes
  • \*Age 20 years or older
  • \*The patients that diabetes treatment does not have a change more than the past two months
  • \* In more than 6\.0% and regulation are less than \+\-10% of patients each HbA1c of most recent two times
  • \*Ability to give written informed consent

Exclusion Criteria

  • \*Patients with type 1 diabetes
  • \*History of severe ketosis, diabetic coma or previous coma within 6 months
  • \*Patients with severe infectious disease ,before or after surgery, or sever trauma
  • \*Occurrence of stroke, myocardial infarction or vascular complication required hospitalization within 6 months
  • \*Under treatment with SGLT\-2 inhibitors
  • \*Pregnant, women on lactation or possibly pregnant women, or plan to pregnant during the study
  • \*History of hypersensitivity to tofogliflozin
  • \*Ineligible patients according to the investigator's judgment

Outcomes

Primary Outcomes

Not specified

Similar Trials